Valuation
- Market cap
- 1,374,000
- Revenue TTM
- $0
- Net income TTM
- $-3,850,000
- PE ratio
- 0.00
- Forward PE
- 0.12
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 92,815
- Avg volume
- 1,499,342
- Day's range
- $0.56 – $0.67
- Shares out
- 2,370,000
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $12.00
Company profile
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is...
Show more
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 941 225 2515
- Website
- https://lakewoodamedex.com
- Address
- 8031 Cooper Creek Blvd., Suite 103, University Park, United States
Latest news
No headlines yet.
